Thyroid cancer screening hits the right note
Researchers from France discovered a thyroid cancer screening technique that...Read more on AuntMinnie.comRelated Reading: Ultrasound: The 60-year-old modality of the future Expanded Medicaid tied to more thyroid cancer diagnoses Doctors order thyroid ultrasounds without good reasons Laryngeal ultrasound helps detect vocal cord polyps Is thyroid cancer overdiagnosed for 9/11 first responders? (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - January 13, 2021 Category: Radiology Source Type: news

New Developments in Thyroid Cancer New Developments in Thyroid Cancer
In this conversation, thyroid cancer experts Drs Megan Haymart and Frank Worden share the latest findings surrounding this increasingly common malignancy.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 12, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Most Docs Lack Confidence in Using Ultrasound for Thyroid Cancer Surveillance Most Docs Lack Confidence in Using Ultrasound for Thyroid Cancer Surveillance
Just one in five physicians who monitor patients for recurrence of differentiated thyroid cancer (DTC) has high confidence in their ability to use ultrasound for surveillance, new research shows.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - January 6, 2021 Category: Radiology Tags: Hematology-Oncology News Source Type: news

In-utero exposures associated with increased risk of thyroid cancer
(The University of Bergen) A recent study shows that thyroid cancer is related to in-utero exposures. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 5, 2021 Category: Cancer & Oncology Source Type: news

Throat cancer symptoms: The most common symptoms of the deadly disease
THROAT cancer is a generic term to describe various types of cancers that affect the area of the throat. It can mean cancer of the thyroid gland, gullet or wind pipe, which have different symptoms. What are they? (Source: Daily Express - Health)
Source: Daily Express - Health - December 19, 2020 Category: Consumer Health News Source Type: news

Thyroid cancer: Do you have a painful lump on your neck? Early sign of the deadly disease
THYROID cancer is a rare type of cancer that affects the thyroid gland. The signs and symptoms are not always obvious until it is too late. A lump which appears on the neck could be a warning sign of the disease. (Source: Daily Express - Health)
Source: Daily Express - Health - December 14, 2020 Category: Consumer Health News Source Type: news

International Study Shows that Active Surveillance Holds Promise as a Treatment Option for Low-Risk Thyroid Cancer
Results from a new study co-led by researchers at Dartmouth’s Geisel School of Medicine and the Department of Surgery at Kuma Hospital in Kobe, Japan, show that active surveillance can be successfully implemented as a viable treatment option for patients with low-risk thyroid cancer. (Source: News at Dartmouth Medical School)
Source: News at Dartmouth Medical School - December 7, 2020 Category: Hospital Management Authors: Timothy Dean Tags: News Press Release Research The Dartmouth Institute thyroid cancer Source Type: news

Study shows that active surveillance holds promise as a treatment option for low-risk thyroid cancer
(The Geisel School of Medicine at Dartmouth) Results from a new study co-led by researchers at Dartmouth's Geisel School of Medicine and the Department of Surgery at Kuma Hospital in Kobe, Japan, show that active surveillance can be successfully implemented as a viable treatment option for patients with low-risk thyroid cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 7, 2020 Category: Cancer & Oncology Source Type: news

Thyroid cancer symptoms: Do you have a lump on your neck? How to tell it is cancerous
THYROID cancer is a relatively uncommon type of cancer, with there being around 3,700 new thyroid cancer cases in the UK every year. A lump in the neck is one of the main warning signs - but when should you be worried? (Source: Daily Express - Health)
Source: Daily Express - Health - December 4, 2020 Category: Consumer Health News Source Type: news

Roche announces FDA approval of Gavreto (pralsetinib) for people with advanced or metastatic RET-mutant and RET fusion-positive thyroid cancers
Basel, 2 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved Gavreto ™ (pralsetinib) for the treatment of adult and paediatric patients 12 years of age and older with advanced or metastatic rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC) who require systemic therapy, or with advanced or metastatic RET fusion-positive thyroid cancer who re quire systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). These indications were approved under the FDA’s accelerated approval...
Source: Roche Media News - December 2, 2020 Category: Pharmaceuticals Source Type: news

Roche announces FDA approval of Gavreto (pralsetinib) for people with advanced or metastatic RET-mutant and RET fusion-positive thyroid cancers
Basel, 2 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved Gavreto ™ (pralsetinib) for the treatment of adult and paediatric patients 12 years of age and older with advanced or metastatic rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC) who require systemic therapy, or with advanced or metastatic RET fusion-positive thyroid cancer who re quire systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). These indications were approved under the FDA’s accelerated approval...
Source: Roche Investor Update - December 2, 2020 Category: Pharmaceuticals Source Type: news

FDA approves pralsetinib for RET-altered thyroid cancers
Hematology / Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 1, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Genentech Announces FDA Approval of Gavreto (pralsetinib) for People With Advanced or Metastatic RET-Mutant and RET Fusion-Positive Thyroid Cancers
South San Francisco, CA -- December 1, 2020 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Gavreto™ (pralsetinib) for the treatment of adult... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 1, 2020 Category: Drugs & Pharmacology Source Type: news

Sussex research points to new effective breast cancer treatment
(Diamond Light Source) An international five-year study led by scientists at the University of Sussex has provided strong evidence for an effective new target for breast cancer treatment. The study, The structure-function relationship of oncogenic LMTK3 being published in Science Advances, involved researchers from seven institutions across three countries including the UKs Diamond Light Source. It suggests LMTK3 inhibitors could be effectively used for treatment of breast cancer, and potentially other types of cancer such as lung, stomach, thyroid and bladder cancer patients (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 13, 2020 Category: Cancer & Oncology Source Type: news

Follow your Endocrine Networks on Twitter
Each of our eight Endocrine Networks now has its own Twitter account, run by the Convenors. Follow them to share news, events, resources, and to keep up to date with your Network colleagues. Get the conversation going in advance of the Network meetings atSfE BES online!The Endocrine Networks are a platform for collaboration between basic and clinical researchers, clinical endocrinologists and endocrine nurses.Go to theMembers' Area to select and update your preferred Networks.Adrenal and Cardiovascular -@adrenalnetwork Dr Scott MacKenzie& Dr Mick O'Reilly Bone& Calcium -@b...
Source: Society for Endocrinology - November 10, 2020 Category: Endocrinology Source Type: news

Thyroid cancer: Lump, swelling and pain in neck are all warning signs to spot
THYROID cancer survival rates are 84 percent for 10 years or more if diagnosed early. Early diagnosis is crucial therefore and spotting the unusual signs could be a matter of life and death. A sign your thyroid cancer has advanced includes these three signs found on your neck. (Source: Daily Express - Health)
Source: Daily Express - Health - November 10, 2020 Category: Consumer Health News Source Type: news

Who's Going to Manage the Thyroid Cancer? Who's Going to Manage the Thyroid Cancer?
Should primary care physicians have a role in managing thyroid cancer patients who require long-term surveillance ? This commentary explores the issue.Journal of Clinical Endocrinology & Metabolism (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 5, 2020 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Is Thyroid Cancer Deadly
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - October 27, 2020 Category: General Medicine Source Type: news

Thyroid cancer: Cushing syndrome is a lesser-known warning sign – what is it?
THYROID cancer survival rates are 84 percent for 10 years or more if diagnosed early. Early diagnosis is crucial therefore and spotting the unusual signs could be a matter of life and death. A sign your thyroid cancer has advanced includes Cushing syndrome. What is it? (Source: Daily Express - Health)
Source: Daily Express - Health - October 24, 2020 Category: Consumer Health News Source Type: news

Impact of Overweight and Obesity on Thyroid Cancer Incidence Impact of Overweight and Obesity on Thyroid Cancer Incidence
The incidence of papillary thyroid cancer is on the rise in recent years, as is the prevalence of obesity. Is there a connection?Journal of the National Cancer Institute (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 23, 2020 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

CMS releases new payment model for radiation oncology
The U.S. Centers for Medicare and Medicaid Services (CMS) today released its...Read more on AuntMinnie.comRelated Reading: Groups tout value of nuclear medicine to Congress Expanded Medicaid tied to more thyroid cancer diagnoses CMS approves payments for Viz.ai software No need to defer cancer treatment for fear of COVID-19 Radiology's declining reimbursement spans over a decade (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 18, 2020 Category: Radiology Source Type: news

Expanded Medicaid tied to more thyroid cancer diagnoses
Expanded Medicaid coverage was linked to the diagnosis of more thyroid cancer...Read more on AuntMinnie.comRelated Reading: Some cancers found earlier after Medicaid expansion Medicaid expansion tied to early breast cancer diagnosis Medicaid expansion under ACA linked to fewer cancer deaths Is thyroid cancer overdiagnosed for 9/11 first responders? Medicaid expansion boosted cancer screening rates (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 18, 2020 Category: Radiology Source Type: news

17.09.20: ESMO Virtual Congress 2020:
New data reinforce strong clinical profile of Vitrakvi™ for patients of all ages with TRK Fusion Cancer including lung and thyroid tumors78% overall response rate (ORR) and median progression-free survival (PFS) of more than 3 years (36.8 months) demonstrate extended benefit in updated data set of 175 adults and children / Majority of adverse events were grade 1 or 2; no new safety signals identified / Consistently high ORRs shown in lung and thyroid data subsets (71 and 75%, respectively) as well as long durability (estimated duration of response at 12 months of 88% and 95%, respectively) / Among patients from integ...
Source: Bayer IR Newsfeed: Events - September 17, 2020 Category: Pharmaceuticals Source Type: news

Cancer Incidence Up for Adolescents and Young Adults
2007 to 2016 saw increase in overall cancer incidence in all age groups, mainly driven by thyroid cancer (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 17, 2020 Category: Cancer & Oncology Tags: Dermatology, Endocrinology, Family Medicine, Gastroenterology, Gynecology, Internal Medicine, Nephrology, Nursing, Oncology, Pediatrics, Journal, Source Type: news

Roche to present a broad range of data across multiple cancer types at the ESMO Virtual Congress 2020
Basel, 17 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that results from a number of studies across its broad oncology portfolio will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, which will be held 19-21 September, 2020. Results include data from three phase III studies across the Tecentriq® (atezolizumab) triple-negative breast cancer (TNBC) programme. Central nervous system (CNS) efficacy data from integrated analyses of the pivotal phase II Rozlytrek® STARTRK-2, phase I STARTRK-1, and phase I ALKA-372-001 trials will be presented in addition to re...
Source: Roche Media News - September 17, 2020 Category: Pharmaceuticals Source Type: news

Roche to present a broad range of data across multiple cancer types at the ESMO Virtual Congress 2020
Basel, 17 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that results from a number of studies across its broad oncology portfolio will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, which will be held 19-21 September, 2020. Results include data from three phase III studies across the Tecentriq® (atezolizumab) triple-negative breast cancer (TNBC) programme. Central nervous system (CNS) efficacy data from integrated analyses of the pivotal phase II Rozlytrek® STARTRK-2, phase I STARTRK-1, and phase I ALKA-372-001 trials will be presented in addition to re...
Source: Roche Investor Update - September 17, 2020 Category: Pharmaceuticals Source Type: news

Congratulations to the winners of the Society ’s 2020 Journal Awards
The Society’s Journal Awards recognise articles from each of the Society-owned journals for excellence in both research focus and practice. Journal of EndocrinologyAndrogens modulate glucocorticoid receptor activity in adipose tissue and liver Dieuwertje C E Spaandermanet al. Journal of Molecular EndocrinologyCrosstalk of BMP-4 and RA signaling pathways on Pomc gene regulation in corticotrophs Leandro Nieto and Mariana Fuerteset al.Endocrine ConnectionsGenotype and phenotype landscape of MEN2 in 554 medullary thyroid cancer patients: the BrasMEN study Rui M B Maciel and Cleber P Camach et al.&am...
Source: Society for Endocrinology - September 14, 2020 Category: Endocrinology Source Type: news

08.09.20: Not intended for U.S. and UK Media
Bayer to showcase new data from evolving Oncology portfolio at ESMO Virtual Congress 2020Long-term efficacy and safety results for larotrectinib (Vitrakvi™) from an integrated data set of adult and pediatric patients with TRK fusion cancer, as well as sub-analyses in advanced thyroid and lung cancer patients / Tolerability and treatment response data from the Phase III ARAMIS trial investigating darolutamide (Nubeqa™) in men with non-metastatic castration-resistant prostate cancer (nmCRPC) / Continued research to explore potential of marketed products, evaluating regorafenib (Stivarga™) and radium-223 dic...
Source: Bayer IR Newsfeed: Events - September 8, 2020 Category: Pharmaceuticals Source Type: news

Roche announces FDA approval of Gavreto (pralsetinib) for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer
             Basel, 7 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the United States (US) Food and Drug Administration (FDA) has approved Gavreto ™ (pralsetinib) for the treatment of adults with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test. This indication was approved under the FDA’s Accelerated Approval programme, based on data from the phase I/II ARROW study. Continued approval for this indication may be contingent upon verifica...
Source: Roche Investor Update - September 7, 2020 Category: Pharmaceuticals Source Type: news

Roche announces FDA approval of Gavreto (pralsetinib) for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer
             Basel, 7 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the United States (US) Food and Drug Administration (FDA) has approved Gavreto ™ (pralsetinib) for the treatment of adults with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test. This indication was approved under the FDA’s Accelerated Approval programme, based on data from the phase I/II ARROW study. Continued approval for this indication may be contingent upon verifica...
Source: Roche Media News - September 7, 2020 Category: Pharmaceuticals Source Type: news

Selpercatinib'Poised to Alter the Landscape' of RET+ve Cancers Selpercatinib'Poised to Alter the Landscape' of RET+ve Cancers
Selpercatinib induced high response rates in patients with RET-altered non-small cell lung cancer and medullary thyroid cancer.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 26, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Many Thyroid Cancer Ultrasound Scans Unnecessary
Title: Many Thyroid Cancer Ultrasound Scans UnnecessaryCategory: Health NewsCreated: 8/25/2020 12:00:00 AMLast Editorial Review: 8/26/2020 12:00:00 AM (Source: MedicineNet Thyroid General)
Source: MedicineNet Thyroid General - August 26, 2020 Category: Endocrinology Source Type: news

Strong, durable responses to selpercatinib in RET-driven medullary thyroid cancer
(Massachusetts General Hospital) Selpercatinib (Retevmo), a drug targeted precisely against cancers driven by mutations or alterations in the gene RET, was effective in a clinical trial at shrinking tumors in patients with medullary thyroid cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 26, 2020 Category: Cancer & Oncology Source Type: news

Many Thyroid Cancer Ultrasound Scans Unnecessary
TUESDAY, Aug. 25, 2020 -- As many as one-third of doctors may be sending patients for a thyroid ultrasound for reasons not supported by guidelines, a new study finds. The use of ultrasound to detect thyroid cancer has led to a large increase in... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 25, 2020 Category: General Medicine Source Type: news

Targeted Treatment Tied to Survival for Anaplastic Thyroid Cancer Targeted Treatment Tied to Survival for Anaplastic Thyroid Cancer
With the introduction of targeted treatments for anaplastic thyroid carcinoma, patients have seen significant improvements in survival, according to a new report.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - August 21, 2020 Category: Surgery Tags: Hematology-Oncology News Source Type: news

What Are the Warning Signs of Thyroid Cancer?
Title: What Are the Warning Signs of Thyroid Cancer?Category: Diseases and ConditionsCreated: 8/14/2020 12:00:00 AMLast Editorial Review: 8/14/2020 12:00:00 AM (Source: MedicineNet Thyroid General)
Source: MedicineNet Thyroid General - August 14, 2020 Category: Endocrinology Source Type: news

What Happens to Your Body When You Have Thyroid Cancer?
Title: What Happens to Your Body When You Have Thyroid Cancer?Category: Diseases and ConditionsCreated: 8/14/2020 12:00:00 AMLast Editorial Review: 8/14/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - August 14, 2020 Category: Cancer & Oncology Source Type: news

Doctors order thyroid ultrasounds without good reasons
About one-third of physicians have ordered thyroid ultrasound scans for patients...Read more on AuntMinnie.comRelated Reading: Is thyroid cancer overdiagnosed for 9/11 first responders? Does thyroid cancer screening lead to overdiagnosis? CT radiation increases risk of thyroid cancer, leukemia AI boosts ultrasound for thyroid cancer screening New thyroid test could help patients avoid surgery (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - August 13, 2020 Category: Radiology Source Type: news

Some physicians are ordering thyroid tests for unsupported reasons
(Michigan Medicine - University of Michigan) Up to one-third of physicians reported sending patients for a thyroid ultrasound for reasons not supported by clinical care guidelines, a new study led by University of Michigan Rogel Cancer Center researchers finds. Routine use of ultrasounds to detect cancerous thyroid nodules have led to a significant increase in thyroid cancer cases in recent years, although many are low-risk and unlikely to cause serious harm. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 12, 2020 Category: International Medicine & Public Health Source Type: news

Rozlytrek, Roche ’s first tumour-agnostic therapy, approved in Europe for people with NTRK fusion-positive solid tumours and for people with ROS1-positive advanced non-small cell lung cancer
             Basel, 03 August 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has granted conditional marketing authorisation for Rozlytrek®(entrectinib) for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor, who have no satisfactory t...
Source: Roche Investor Update - August 3, 2020 Category: Pharmaceuticals Source Type: news

Rozlytrek, Roche ’s first tumour-agnostic therapy, approved in Europe for people with NTRK fusion-positive solid tumours and for people with ROS1-positive advanced non-small cell lung cancer
             Basel, 03 August 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has granted conditional marketing authorisation for Rozlytrek®(entrectinib) for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor, who have no satisfactory t...
Source: Roche Media News - August 3, 2020 Category: Pharmaceuticals Source Type: news

A Viewer Spotted a Lump on Her Neck. Now, She ’s Having a Tumor Removed.
Victoria Price, an investigative reporter in Tampa, Fla., said she was grateful that a viewer sent her a terse email suggesting that she get her thyroid checked out. (Source: NYT Health)
Source: NYT Health - July 25, 2020 Category: Consumer Health News Authors: Johnny Diaz Tags: Thyroid Cancer Neck Price, Victoria Television News and News Media Surgery and Surgeons Source Type: news

Comparing hyperthyroidism treatments with risk of cancer death
(JAMA Network) Researchers compared long-term risk of death from a solid cancer in patients treated with radioactive iodine, anti-thyroid drugs or surgery for hyperthyroidism. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - July 23, 2020 Category: International Medicine & Public Health Source Type: news

New special issue on hereditary endocrine tumours published in Endocrine-Related Cancer
The Society for Endocrinology journal,Endocrine-Related Cancer, has recently published a special issue on‘Hereditary endocrine tumours: Current state-of-the-art and research opportunities’. It is guest edited by Steven Waguespack and Constantine Stratakis, and contains eight free-to-read reviews covering topics such as: •New and future perspectives for parathyroid carcinoma•The state of science in medullary thyroid carcinoma: current challenges and unmet needs•Challenges and opportunities in genetic counseling for hereditary endocrine neoplasia syndromes• GPR...
Source: Society for Endocrinology - July 21, 2020 Category: Endocrinology Source Type: news

Roche collaborates with Blueprint Medicines to bring a new treatment to people with RET-altered cancers
Basel, 14 July 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Blueprint Medicines Corporation (NASDAQ:BPMC), today announced the signing of a licensing and collaboration agreement providing exclusive rights to Roche for global co-development and commercialisation outside the United States (US), excluding Greater China*. In the US, Genentech, a member of the Roche Group, will obtain co-commercialisation rights to pralsetinib, Blueprint Medicine ’s investigational, once-daily oral precision therapy for the treatment of people with RET-altered non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC) and other t...
Source: Roche Investor Update - July 14, 2020 Category: Pharmaceuticals Source Type: news

Roche collaborates with Blueprint Medicines to bring a new treatment to people with RET-altered cancers
             Basel, 14 July 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Blueprint Medicines Corporation (NASDAQ:BPMC), today announced the signing of a licensing and collaboration agreement providing exclusive rights to Roche for global co-development and commercialisation outside the United States (US), excluding Greater China*. In the US, Genentech, a member of the Roche Group, will obtain co-commercialisation rights to pralsetinib, Blueprint Medicine ’s investigational, once-daily oral precision therapy for the treatment of people with RET-altered ...
Source: Roche Media News - July 14, 2020 Category: Pharmaceuticals Source Type: news

Blueprint Medicines Announces Submission of New Drug Application to FDA for Pralsetinib for the Treatment of Advanced RET Mutant and RET Fusion-Positive Thyroid Cancers
CAMBRIDGE, Mass., July 1, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced the... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - July 1, 2020 Category: Drugs & Pharmacology Source Type: news

3D ultrasound is effective for measuring blood flow
Researchers from across the U.S. confirmed the efficacy of 3D color-flow ultrasound...Read more on AuntMinnie.comRelated Reading: QT Ultrasound touts presentations on 3D ultrasound Researchers develop mini 3D ultrasound for scoliosis Automated 3D US effective for diagnosing hip dysplasia 4D ultrasound contrast HSG assesses fallopian tubes 3D tumor measurements on US spot thyroid cancer growth (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 30, 2020 Category: Radiology Source Type: news

Global Burden of Thyroid Cancer Is Increasing
TUESDAY, June 30, 2020 -- There is an increasing global burden of thyroid cancer, according to a study published online June 26 in JAMA Network Open. YuJiao Deng, Ph.D., from the First Affiliated Hospital of Zhejiang University Hangzhou, China, and... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 30, 2020 Category: Pharmaceuticals Source Type: news

Incidence of thyroid cancer has doubled globally, analysis finds
The number of people diagnosed with thyroid cancer has more than doubled worldwide since 1990, fueled by a rise in cases in Asia. The United States accounts for 10 percent of cases worldwide. (Source: Health News - UPI.com)
Source: Health News - UPI.com - June 26, 2020 Category: Consumer Health News Source Type: news